Biologics Spine BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease byTim AllenMay 7, 2026
Biologics Spine BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease byTim AllenFebruary 10, 2026
Biologics Spine BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data byTim AllenNovember 13, 2024
Regulatory Spine BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment byTim AllenApril 16, 2024
Spine BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergFebruary 5, 2024
Biologics Spine BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting byJosh SandbergFebruary 1, 2024
Biologics Spine BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergSeptember 8, 2023
Biologics BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergJune 12, 2023
Biologics Spine BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 30, 2022
Biologics Spine BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 22, 2022
